Summary
IDEXX Laboratories, Inc. (IDXX) announced on August 1, 2011, the execution of an amended and restated credit agreement. This agreement effectively replaces a previous credit facility and establishes a new five-year unsecured revolving credit facility maturing on July 25, 2016. The facility's aggregate borrowing capacity has been increased from $200 million to $300 million, with an option to further increase it to $450 million under specified conditions, providing the company with enhanced financial flexibility. The primary purpose of these borrowings is for general corporate purposes, supporting the company's ongoing operations and strategic initiatives. The agreement also outlines various borrowing options and interest rate structures, including U.S. Dollars, Canadian Dollars, Euros, and alternative currencies, with rates tied to benchmark rates plus a margin that varies based on the company's consolidated leverage ratio. This structure allows IDEXX to potentially leverage favorable market conditions and its financial health to optimize borrowing costs.
Key Highlights
- 1IDEXX entered into an amended and restated credit agreement for a $300 million unsecured revolving credit facility.
- 2The new facility extends the maturity date to July 25, 2016, providing a five-year term.
- 3The facility capacity has been increased from $200 million to $300 million, with an option to increase up to $450 million.
- 4Borrowings under the agreement are for general corporate purposes.
- 5Interest rates are variable and depend on the currency borrowed and IDEXX's consolidated leverage ratio.
- 6The agreement includes customary covenants, including affirmative, negative, and a financial covenant related to the consolidated leverage ratio.
- 7Subsidiaries are named as borrowers, and certain subsidiaries have guaranteed the obligations.